Journal of Clinical Oncology, Vol 15, 1354-1366, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer [published erratum appears in J Clin Oncol 1997 Jul;15(7):2763]

T Ahlert, W Sauerbrei, G Bastert, S Ruhland, B Bartik, N Simiantonaki, J Schumacher, B Hacker, M Schumacher and V Schirrmacher
Universitats-Frauenklinik Heidelberg, Germany.

PURPOSE: We investigated quality and efficacy criteria of an autologous, physically and immunologically purified, Newcastle disease virus (NDV)-modified, irradiated tumor-cell vaccine (ATV-NDV) by analyzing three independent cohorts (a through c) of patients vaccinated between 1991 and 1995. MATERIALS AND METHODS: Included were 63 patients with primary breast cancer (a), 27 with metastatic pretreated breast cancer (b), and 31 with metastatic pretreated ovarian cancer (c). In addition to vaccine, cohorts b and c received nonspecific immunotherapy as supportive treatment. After cryoconservation and purification, the vaccines varied in applied numbers of viable cells and dead cell contaminations. We retrospectively hypothesized that an immunogenic vaccine should contain at least 1.5 x 10(6) viable tumor cells and viability should be at least 33%. Each cohort was thus divided into two groups; one that received vaccine type A (A), fulfilling both criteria; and the other type B (B), missing one or both criteria. RESULTS: Conventional prognostic factors were wall balanced between A and B in cohorts a and c. In cohort a, there was a benefit in survival (P = .026) and disease- free survival (P = .089) for A. In addition, in cohort a, the relative risk of dying in the group that received A as compared with B was 0.2 (univariate Cox model). There were also survival trends in favor of A versus B (P = .18 and P = .09, respectively) in cohorts b and c, with relative risks of 0.5 and 0.42, respectively. In cohort b, the survival benefit could not be ascribed to vaccine quality alone, because of prognostic imbalance in favor of A. CONCLUSION: In cohort c, like in cohort a, the survival benefit for A may be ascribed to the ATV-NDV vaccine quality, since prognostic factors were not biased. This could imply clinical effectivity in breast and ovarian cancer with ATV-NDV high-quality vaccine. Furthermore, the data provide clinically relevant information for standardization and quality control of autologous tumor- cell vaccines. A randomized study is urgently needed.

This article has been cited by other articles:

				G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. de Braud, A. Cardillo, E. Munzone, A. Rocca, G. Bonizzi, V. Brichard, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann. Onc., May 1, 2006; 17(5): 750 - 762. [Abstract] [Full Text] [PDF]

				L A Emens, R T Reilly, and E M Jaffee Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17. [Abstract] [Full Text] [PDF]

				J. Karcher, G. Dyckhoff, P. Beckhove, C. Reisser, M. Brysch, Y. Ziouta, B. H. Helmke, H. Weidauer, V. Schirrmacher, and C. Herold-Mende Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells Cancer Res., November 1, 2004; 64(21): 8057 - 8061. [Abstract] [Full Text] [PDF]

				H. H. Steiner, M. M. Bonsanto, P. Beckhove, M. Brysch, K. Geletneky, R. Ahmadi, R. Schuele-Freyer, P. Kremer, G. Ranaie, D. Matejic, et al. Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical Benefit J. Clin. Oncol., November 1, 2004; 22(21): 4272 - 4281. [Abstract] [Full Text] [PDF]

				B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides Clinical Studies of Vaccines Targeting Breast Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3222 - 3234. [Abstract] [Full Text] [PDF]